Reardon Andrew

CLO & SecretaryLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Jun 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
9
8 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 1, 2026Option exercise(M)5K$52.27$261K46K
Jun 1, 2026Sell(S)491$223.95$110K46K
Jun 1, 2026Sell(S)677$225.20$152K45K
Jun 1, 2026Sell(S)1K$225.97$324K44K
Jun 1, 2026Sell(S)400$226.78$91K43K
Jun 1, 2026Sell(S)584$228.57$133K43K
Jun 1, 2026Sell(S)1K$229.47$279K42K
Jun 1, 2026Sell(S)200$230.41$46K41K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 1, 2026Option exercise(M)5K$039K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000083) within minutes of acceptance. Every field above traces to the original document. Verify it directly: